TASLY

天士力

Tasly was founded in 1994, focusing primarily on biopharmaceuticals. It is an integrated corporate group that combines biopharmaceuticals, health care, and medical and health management services. The company concentrates on cardiovascular, digestive metabolism, and oncology areas. They have built a modern Chinese medicine system, mainly based on products such as Compound Danshen Dripping Pills, Yangxue Qingnao Granules (Pills), Qishen Yiqi Dripping Pills, and Injectable Yiqi Fumai.

Tasly adopts an international perspective, taking the big health industry as the main focus, life sciences as the core, and the life and health industry as its collaboration. The core enterprise, Tasly Pharmaceutical Group Co., Ltd., was listed on the Shanghai Stock Exchange in 2002.

Tasly Pharmaceutical Group is committed to the development of the life sciences within the big health industry system. Rooted in biopharmaceuticals, regenerative medicine, and biomedical engineering, it insists on high-tech, intellectual, and high-end development. The company has modernized traditional Chinese medicine through international guidance, achieving standardization and intelligence, symbolized by their Compound Danshen Dripping Pills. Through self-development, cooperative development, product introductions, and investment in market licensing rights, the company connects with cutting-edge international technologies to improve chemical medicines and develop innovative biomedicines.

Tasly Health Industry Investment Group focuses on the life and health sector within the big health industry system. Centered on core health elements and individualized user needs, they prioritize resource-based industries, with Guotai Liquor Group as the leading enterprise, driving the development of Tiepoter Tea Precious series, health functional foods, and C-cell vitality mineral water industry. Their focus on technological innovation and product culture enhancement aims to elevate the health product consumption experience.

Tasly adheres to industry-based and finance-supported principles, promoting industry-finance interaction. They have set up an industrial capital platform—Tasly Capital, with “industry + capital” positioning, focusing on specialization and innovation, to empower the physical industry’s innovation and upgrade.

Tasly has established a “research institute without walls,” which has formed a product system that includes drugs for cardiovascular systems, anti-tumor and immune systems, gastrointestinal systems, and antiviral and cold medicines. Modern Chinese medicines like Compound Danshen Dripping Pills and Yangxue Qingnao Granules, and chemical drugs like Tiqing and Shuilinjia have become renowned products.

With rapid enterprise development, Tasly Group has achieved outstanding results in the national pharmaceutical industry. The Compound Danshen Dripping Pills became the first traditional Chinese medicine preparation to be approved by the US FDA for clinical drug applications and has maintained the highest sales record for modern Chinese medicine products for several years. The research of these pills has been listed in key national projects and has received numerous awards. The Tasly Technology Center has been approved as a national enterprise technology center, and a post-doctoral research station has been established by the Ministry of Human Resources.

Looking to the future, Tasly aims to utilize modern technologies like artificial intelligence and big data, speeding up their transformation to an innovative and service-oriented company. They are shifting from “product-centric manufacturing” to “intelligent manufacturing focused on product clustering and industrial systematization.” Centered on building a “big health” ecosystem, they are keen on innovation and persistent development, contributing to building a “Healthy China.”

Best-selling Products from the TASLY Brand：